Giant Cell Arteritis
4
Pipeline Programs
8
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
4100%
+ 6 programs with unclassified modality
Competitive Landscape
7 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
3 programs1
1
1
Secukinumab 300 mg, s.c.Phase 3
Secukinumab 300 mg, s.c.Phase 2
SecukinumabPhase 1Monoclonal Antibody
Chugai PharmaJapan - Tokyo
2 programstocilizumab and IV steroids combinationPHASE_21 trial
TocilizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
Kiniksa PharmaceuticalsMA - Lexington
1 programmavrilimumabPHASE_2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chugai PharmaTocilizumab
Chugai Pharmatocilizumab and IV steroids combination
Kiniksa Pharmaceuticalsmavrilimumab
GenentechTARGET GCAT Registry
Clinical Trials (4)
Total enrollment: 274 patients across 4 trials
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
Start: Sep 2021Est. completion: Aug 202566 patients
Phase 3Active Not Recruiting
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
Start: Sep 2020Est. completion: Dec 202258 patients
Phase 2Unknown
KPL-301 for Subjects With Giant Cell Arteritis
Start: Sep 2018Est. completion: Nov 202070 patients
Phase 2Completed
TARGET GCAT Registry
Start: May 2019Est. completion: Jun 202080 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.